Document is current
Any future updates will be listed below
-
Authors
Radcliffe, Nathan M.
Sheppard, John
Simmons, Blake
Owen, Desiree
Nguyen, Ashley
Cavanagh, Bill
Brady, Todd C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04735393 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease
https://doi.org/10.1007/s40123-026-01379-0
-
Funding
Funding for this research was provided by:
AbbVie
Aldeyra Therapeutics
- License Information
-
More Information
Article History
Received: 11 February 2026
Accepted: 24 March 2026
First Online: 11 April 2026
Declarations
:
: Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Nathan M. Radcliffe is a consultant for AbbVie, Alcon, Bausch + Lomb, Harrow, Tarsus, and Théa. John Sheppard is a consultant for Bausch + Lomb, GmbH, Harrow, and Novaliq. Blake Simmons was an investigator in other studies of reproxalap. Desiree Owen and Ashley Nguyen are employees of AbbVie and may own stock/stock options. Bill Cavanagh and Todd C. Brady are employees of Aldeyra Therapeutics.
: The clinical trial was performed in accordance with Good Clinical Practice, applicable regulations, and the principles of the Declaration of Helsinki. An institutional review board (Alpha IRB, San Clemente, CA, USA) or independent ethics committee approved the protocol, informed consent forms, and recruitment materials at each site before patient enrollment, and all patients provided written informed consent at screening before undergoing any trial-related procedure.
